3/5
07:56 am
hrow
Harrow (HROW) was downgraded by Zacks Research from "hold" to "strong sell".
Medium
Report
Harrow (HROW) was downgraded by Zacks Research from "hold" to "strong sell".
3/4
08:04 am
hrow
Harrow (HROW) had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an "overweight" rating on the stock.
Low
Report
Harrow (HROW) had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an "overweight" rating on the stock.
3/4
08:00 am
hrow
Harrow (HROW) had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Harrow (HROW) had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a "buy" rating on the stock.
3/4
07:25 am
hrow
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference [Yahoo! Finance]
Low
Report
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference [Yahoo! Finance]
3/4
07:00 am
hrow
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
Low
Report
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
3/3
05:03 pm
hrow
Harrow (HROW) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Harrow (HROW) had its "outperform" rating reaffirmed by William Blair.
3/3
02:33 pm
hrow
Harrow Shares Collapse, Another Opportunity? [Seeking Alpha]
Low
Report
Harrow Shares Collapse, Another Opportunity? [Seeking Alpha]
3/3
11:16 am
hrow
Harrow (HROW) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Harrow (HROW) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/3
07:00 am
hrow
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
High
Report
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
3/2
04:40 pm
hrow
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance [Yahoo! Finance]
High
Report
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance [Yahoo! Finance]
3/2
04:05 pm
hrow
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
High
Report
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
2/28
09:41 am
hrow
Harrow, Inc. (HROW): A Bull Case Theory [Yahoo! Finance]
Low
Report
Harrow, Inc. (HROW): A Bull Case Theory [Yahoo! Finance]
2/18
07:00 am
hrow
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Low
Report
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
2/17
07:00 am
hrow
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
Medium
Report
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
2/4
06:44 am
hrow
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/3
05:00 am
hrow
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Medium
Report
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
2/2
07:00 am
hrow
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Medium
Report
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
1/22
06:23 pm
hrow
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
Medium
Report
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
1/19
06:15 am
hrow
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
Low
Report
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]